Basic & Clinical Medicine ›› 2026, Vol. 46 ›› Issue (8): 1103-1108.doi: 10.16352/j.issn.1001-6325.2026.08.1103

• Original Articles • Previous Articles     Next Articles

Overexpression of miR-130a-3p enhances chemoradiotherapy sensitivity of human cervical cancer cell line Caski

HAN Chao, KONG Weimin*, SONG Dan   

  1. Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China
  • Received:2025-09-02 Revised:2026-03-18 Published:2026-07-22
  • Contact: *kwm1967@ccmu.edu.cn

Abstract: Objective To explore the impact of miR-130a-3p on the sensitivity of human cervical cancer cell line Caski to chemoradiotherapy. Methods The cells were divided into four groups: the control group (Caski cell line), cisplatin-resistant group (Caski/DDP cells), miR-130a-3p overexpression group (Caski+miR-130a-3p cells), and cisplatin-resistant miR-130a-3p overexpression group (Caski/DDP+miR-130a-3p cells). After treatment with various concentrations of cisplatin and radiotherapy, cell proliferation was assessed using the CCK-8 assay, cell apoptosis was measured by flow cytometry, and the expression of ZEB1 protein was detected by Western blot. Results After overexpression of miR-130a-3p, the IC50 of cisplatin in Caski cells decreased significantly (9.447 μg/mL vs. 6.429 μg/mL, P<0.05), and the apoptosis rate increased, although the difference was not statistically significant (mean apoptosis rate 29.3% vs. 30.6%, P>0.05), and the expression of ZEB1 was significantly downregulated (P<0.01). In Caski/DDP cell strain, the IC50 decreased more markedly after overexpression of miR-130a-3p (IC50: 58.38 μg/mL vs. 18.38 μg/mL, P<0.000 1); the rate of cell apoptosis increased significantly (mean apoptosis rate: 15.9% vs. 29.8%, P<0.001), and the expression of ZEB1 protein was downregulated (P<0.01). Conclusions Overexpression of miR-130a-3p may increase the chemoradiotherapy sensitivity of cervical cancer cells by downregulating ZEB1 expression.

Key words: miR-130a-3p, cervical cancer cell, ciplatin resistance, radiochemotherapy

CLC Number: